Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling.

@article{Macdonald2012RandomizedTO,
  title={Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling.},
  author={Robert L Macdonald and Randall Higashida and Emanuela Keller and Stephan A. Mayer and A Molyneux and Andreas Raabe and Peter Vajkoczy and Isabel Wanke and Doris Bach and Aline Frey and Pegah Nowbakht and S{\'e}bastien Roux and Neal F. Kassell},
  journal={Stroke},
  year={2012},
  volume={43 6},
  pages={1463-9}
}
BACKGROUND AND PURPOSE Clazosentan, an endothelin receptor antagonist, has been shown to reduce vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). CONSCIOUS-3 assessed whether clazosentan reduced vasospasm-related morbidity and all-cause mortality postaSAH secured by endovascular coiling. METHODS This double-blind, placebo-controlled, phase III trial randomized patients with aSAH secured by endovascular coiling to ≤ 14 days intravenous clazosentan (5 or 15 mg/h) or placebo. The… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
50 Citations
21 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Similar Papers

Loading similar papers…